Literature DB >> 31042259

Assessment of the Development of New Regional Dermatoses in Patients Treated for Atopic Dermatitis With Dupilumab.

Gefei Alex Zhu1, Jennifer K Chen1, Albert Chiou1, Justin Ko, Golara Honari1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31042259      PMCID： PMC6495362          DOI： 10.1001/jamadermatol.2019.0109

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

1.  Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways.

Authors:  Timo Buhl; Mathias Sulk; Pawel Nowak; Jörg Buddenkotte; Ian McDonald; Jérôme Aubert; Isabelle Carlavan; Sophie Déret; Pascale Reiniche; Michel Rivier; Johannes J Voegel; Martin Steinhoff
Journal:  J Invest Dermatol       Date:  2015-04-07       Impact factor: 8.551

2.  Dupilumab use in allergic contact dermatitis.

Authors:  Brian C Machler; Calvin T Sung; Evan Darwin; Sharon E Jacob
Journal:  J Am Acad Dermatol       Date:  2018-08-06       Impact factor: 11.527

3.  Inhibition of allergic contact dermatitis to DNCB but not to oxazolone in interleukin-4-deficient mice.

Authors:  C Traidl; F Jugert; T Krieg; H Merk; N Hunzelmann
Journal:  J Invest Dermatol       Date:  1999-04       Impact factor: 8.551

4.  Clinical and immunological responses in ocular demodecosis.

Authors:  Jae Hoon Kim; Yeoun Sook Chun; Jae Chan Kim
Journal:  J Korean Med Sci       Date:  2011-09-01       Impact factor: 2.153

5.  The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy.

Authors:  Raagini Suresh; Jenny E Murase
Journal:  JAAD Case Rep       Date:  2018-10-03
  5 in total
  8 in total

1.  Dupilumab facial redness: Positive effect of itraconazole.

Authors:  Fleur S A de Beer; Daphne S Bakker; Inge Haeck; Lieneke Ariens; Jorien van der Schaft; Marijke R van Dijk; Marjolein S de Bruin-Weller
Journal:  JAAD Case Rep       Date:  2019-10-22

2.  Nomenclature and clinical phenotypes of atopic dermatitis.

Authors:  Giampiero Girolomoni; Marjolein de Bruin-Weller; Valeria Aoki; Kenji Kabashima; Mette Deleuran; Luis Puig; Ashish Bansal; Ana B Rossi
Journal:  Ther Adv Chronic Dis       Date:  2021-03-26       Impact factor: 5.091

3.  Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib.

Authors:  Jannett Nguyen; Jennifer K Chen; Golara Honari; Marlyanne Pol-Rodriguez; Justin M Ko; Albert S Chiou
Journal:  JAAD Case Rep       Date:  2020-11-06

Review 4.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

5.  Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients.

Authors:  Young Jae Kim; Mi Young Lee; Chong Hyun Won
Journal:  Asia Pac Allergy       Date:  2022-01-10

6.  Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.

Authors:  Andrew Alexis; Marjolein de Bruin-Weller; Stephan Weidinger; Weily Soong; Sebastien Barbarot; Ileana Ionita; Fan Zhang; Hernan Valdez; Claire Clibborn; Natalie Yin
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-17

7.  Dupilumab-Associated Head and Neck Dermatitis With Ocular Involvement in a Ten-Year-Old With Atopic Dermatitis: A Case Report and Review of the Literature.

Authors:  Arthur M Samia; Lyda Cuervo-Pardo; Marjorie E Montanez-Wiscovich; Vanessa Y Cavero-Chavez
Journal:  Cureus       Date:  2022-07-23

Review 8.  Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases.

Authors:  Fumi Miyagawa
Journal:  Biomedicines       Date:  2022-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.